Mountain View, CA USA and Oslo, NORWAY – Cordance Medical, a leading innovator in non-invasive opening of the blood-brain barrier (BBB), and EXACT Therapeutics, a clinical-stage Norwegian biopharmaceutical precision health company developing Acoustic Cluster Therapy (ACT®), today announced a strategic partnership aimed at combining their breakthrough technologies to revolutionize drug delivery in the treatment of brain diseases.
Cordance Medical’s NeuroAccess™ platform is designed to provide personalized, targeted opening of the BBB in a non-invasive, painless procedure designed to take 30 minutes or less. This groundbreaking technology allows the procedure to be performed in space-constrained environments such as community outpatient clinics and infusion treatment centers, making it more accessible to patients worldwide.
EXACT Therapeutics’ ACT® platform utilizes a unique approach to ultrasound-mediated, targeted drug enhancement. Their proprietary formulation, PS101, consists of highly engineered microbubble-microdroplet clusters that can be co-administered intravenously with a therapeutic agent. The ACT® formulation is activated by ultrasound, enabling precise targeting of therapeutic enhancement to the desired location.
This strategic partnership will combine Cordance Medical’s NeuroAccess™ platform and EXACT Therapeutics’ ACT® technology, with the aim of delivering more effective drug therapy across the BBB. By integrating the two technologies, patients suffering from various brain diseases, including brain tumors and neurodegenerative disorders, will have access to cutting-edge, targeted treatment options in upcoming clinical trials.
“We are excited to partner with EXACT Therapeutics and leverage their proprietary ACT® technology,” said Ryan Dittamore, CEO of Cordance Medical. “Our combined technologies have the potential to significantly improve drug delivery to the brain, resulting in better patient outcomes and accessibility to innovative non-invasive treatments.”
Per Walday, CEO of EXACT Therapeutics added, “Cordance Medical’s NeuroAccess™ platform is an ideal complement to our ACT® technology. This partnership represents a significant milestone in our mission to broaden and enhance the clinical utility of a wide range of therapeutic agents across various indications. We are committed to working together to transform the treatment landscape for patients with brain diseases.”
About Cordance Medical
Cordance Medical is a leading medical technology company focused on developing innovative, non-invasive solutions for opening the blood-brain barrier. The company’s flagship product, the NeuroAccess platform, is designed to provide personalized, targeted treatment in a painless procedure designed to be 30 minutes or less. Cordance Medical is dedicated to improving patient outcomes and increasing accessibility to advanced medical treatments.
About EXACT Therapeutics
EXACT Therapeutics is a clinical-stage Norwegian biopharmaceutical company specializing in ultrasound-mediated drug delivery. Their proprietary Acoustic Cluster Therapy (ACT®) platform follows a unique approach to targeted drug enhancement, with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across multiple indications, including oncology and brain diseases.
For more information, please contact:
Cordance Medical:
Ryan Dittamore, CEO
Email: ryan.dittamore@cordancemedical.com
EXACT Therapeutics:
Per Walday, CEO
Email: per.walday@exact-tx.com
